Dyadic International, Inc. is a biotechnology company that has developed innovative microbial platforms to address the increasing global demand for protein production and biopharmaceuticals. The company utilizes its proprietary C1 platform, which is based on a genetically engineered thermophilic filamentous fungus, to produce a variety of proteins, including vaccines, antibodies, and therapeutic treatments. This platform is designed to be highly productive and scalable, allowing for the economical manufacture of biopharmaceutical products in larger quantities. Additionally, Dyadic's Dapibus™ protein production platform focuses on the rapid development of low-cost proteins and biologic products for non-pharmaceutical applications, such as food and nutrition, thereby addressing global protein shortages.

Dyadic's commitment to advancing biotechnology is evident in its active pipeline, which includes a range of vaccines, therapeutic proteins, and diagnostic products. The company aims to meet the unmet clinical needs for effective and affordable biopharmaceuticals for both human and animal health. By leveraging its extensive experience in microbial biomanufacturing, Dyadic is positioned to tackle the challenges of producing high-quality proteins at low costs, especially in light of increasing global demands exacerbated by factors such as pandemics and climate change. Through partnerships and collaborations, Dyadic seeks to enable the development of next-generation proteins that can significantly improve health outcomes worldwide.

United States

Dyadic International, Inc. (Nasdaq: DYAI) - We are a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system - but most importantly to save lives.

Dyadic International, Inc.

Company Details